|
|
“DESIGN proteins and peptides
with DESIRED properties and
IMPACT the biologics PIPELINE.” |
Overview
Scientific Advisory Board
Dr. Andrew M. Bradbury, Staff Scientist, Biosciences, Los Alamos National Laboratory
Dr. Thomas O. Daniel, Chief Scientific Officer, Ambrx, Inc.
Dr. Lutz Jermutus, Director of Protein Engineering, Drug Discovery, Cambridge Antibody Technology Ltd.
Dr. Richard W. Wagner, Executive Vice President, Science & Technology, Praecis Pharmaceuticals Inc.
Dr. Gregory A. Weiss, Assistant Professor of Chemistry, University of California, Irvine
Dr. K. Dane Wittrup, J.R. Mares Professor, Chemical Engineering & Bioengineering, Massachusetts Institute of Technology
|
Keynote Presentation
|
|
|
Future of Protein Therapeutics
Dr. Jürgen Drews, Bear Stearns Health Innoventures Management L.L.C.
|
|
Improved Library Design:
Faster and More Efficient Screening
Modulating Protein-Protein Interactions with Cyclic Peptides
Dr. Alexander R. Horswill, Pennsylvania State University
On-Chip Display Library Screening
Dr. Patrick S. Daugherty, Assistant Professor, Department of Chemical Engineering, University of California, Santa Barbara
Computational Design of Protein Combinatorial Libraries
Dr. Costas Maranas, Pennsylvania State University
Comparison of Diversity in T7 and M13 -Displayed Libraries
Dr. Toshiyuki Mori, National Cancer Institute
Optimizing Protein Design
Selection of Peptide Analog Ligands by Pure Translation Display
Dr. Anthony C. Forster, Vanderbilt University Medical Center
Designed Ankyrin Repeat Proteins
Dr. Kaspar Binz, University of Zürich
Structure Determination of Phage and Displayed Peptides
Prof. Stanley Opella, University of California, San Diego
Affilin™ - Alternatives for Chromatography and Therapy
Dr. Gabriele Proetzel, CSO, R & D, Scil Proteins GmbH
Design and Application of Synthetic Antibodies
Dr. Sachdev Sidhu, Genentech Inc.
Protein Medicinal Chemistry:
Creative Solutions for Protein Therapeutics
Engineering Antibodies for Drug Conjugation for Cancer Therapy
Dr. Paul J. Carter, Seattle Genetics, Inc.
Optimized Antibody Therapeutics via Fc Engineering
Dr. Bassil I. Dahiyat, Xencor, Inc.
Engineering the Next Generation of Therapeutic Proteins
Dr. Ho Sung Cho, Ambrx, Inc.
Optimizing Biologics by Ribosome Display
Dr. Ralph Minter, Cambridge Antibody Technology
Engineering Proteins Without DNA
Dr. Gerd G. Kochendoerfer, Director, Research & Development, Gryphon Therapeutics
Successful Drugs Engineered Through Phage
DisPLAY
|
Transition Keynote:
|
|
|
From Phage Display to Recombinant Antibodies
Anti-IL12 Antibody Development and Clinical Trial Data
Dr. Jochen Salfeld, Abbott Bioresearch Center |
|
Peptibodies: A Novel Therapeutic Platform
Dr. Hosung Min, Amgen Inc.
A Virus-Neutralizing Antibody that Targets the HIV-1 Fusion Machinery
Dr. Romas Geleziunas, Merck Research Laboratories
Development of Potent Cytokine Inhibitors as Therapeutic Antibodies
Dr. Davinder Gill, Wyeth Pharmaceuticals
Drug Candidates from Phage Display: Discovery to Development
Dr. E. Fayelle Whelihan, Dyax Corp.
Call for Sponsors and Exhibitors
Showcase your company’s expertise, brand your solutions and develop revenue opportunities with qualified
decision-makers
by becoming an Exhibitor or Sponsor of PEGS: The Protein Engineering Summit. We have a number of
opportunities available, including 30-minute technology workshop presentations. To discuss sponsoring or exhibiting at this conference, please contact Carol
Dinerstein at 781-972-5471 or dinerstein@healthtech.com.
|
